Bone Turnover Responses to Changed Physical Activity

The aim of the study was to compare bone turnover in male soccer players with controls and to follow bone turnover with changes in activity level. Serum-osteocalcin (OC), carboxy-terminal propeptide of type I collagen (PICP) and total alkaline phosphatases (tALP) were measured to assess bone formation. Bone resorption was detected by carboxyterminal cross-linked telopeptide of type I collagen (ICTP). Bone turnover of 12 male premier league soccer players (mean age 23 years, range, 17–34) exercising 12 hours/week (range, 8–15) were at the last day of the soccer season compared with 27 age- and gender-matched controls. Bone turnover was followed weekly during a 4-week resting period between two seasons, and a further 10 days following resumption of full training. Data are presented as mean ± SEM. Both OC (22 ± 12%) and ICTP (34 ± 17%) were higher in the players compared with the controls at the end of the season (both P < 0.05, respectively). After 2 weeks of reduced physical activity among the athletes, the PICP levels were 21 ± 4% (P < 0.05) lower and the ICTP levels 8 ± 12% higher (P = 0.07) compared with baseline. OC, PICP, and tALP was then no different compared with controls and ICTP was higher than controls (P < 0.001). Ten days within the new season, there was a 23 ± 5% increase in PICP (P < 0.001) and a 4 ± 4% decrease in ICTP (P < 0.05) compared with the end of the resting period. In summary, male soccer players have higher bone turnover compared with age- and gender-matched controls. Changes in physical activity level were associated with changes in bone formation and resorption as evaluated by bone markers within weeks, and after 2 weeks rest, ICTP was higher in the athletes than the controls. We conclude that the higher age-related diminution in BMD, previously reported in former soccer players compared with age- and gender-matched controls, may be the result of increased bone resorption, evaluated by ICTP, compared with the controls.     

Prediction of bone loss using biochemical markers of bone turnover

Summary The association between baseline levels of eleven bone turnover markers and 5-year rate of bone density change was prospectively studied in a population-based sample of 601 75-year-old women. Several bone formation and resorption markers as well as urinary osteocalcin were modestly correlated to rate of bone density change. Introduction Prediction of bone loss by bone turnover markers (BTMs) has been investigated with conflicting results. There is limited information in the elderly. Methods Eleven bone turnover markers were analyzed in 75-year old women in the OPRA study (n = 601) and compared to the 5-year change of areal bone mineral density (aBMD) in seven skeletal regions. Results Annual aBMD change varied between +0.4% (spine) and −2.0% (femoral neck). Significant associations (p < 0.01) were found for four different serum osteocalcins (S-OCs) (standardized regression coefficient −0.20 to −0.22), urinary deoxypyridinoline (−0.19), serum TRACP5b (−0.19), serum CTX-I (−0.21), two of the three urinary osteocalcins (U-OCs) (−0.16) and aBMD change of the leg region (derived from the total body measurement). After adjustment for baseline aBMD, associations were found for all S-OCs (−0.11 to −0.16), two of the three U-OCs (−0.14 to −0.16) and aBMD change at the total hip, and for three of the four S-OCs (−0.14 to −0.15), S-TRACP5b (−0.11), two of the three U-OCs (−0.14 to −0.15) and aBMD change at the femoral neck. There were no significant results concerning aBMD change at the spine. Conclusion This study indicates that BTMs are correlated with aBMD loss in some skeletal regions in elderly women.     

High bone turnover in fibromyalgia

Summary This paper seeks to determine if patients with a fibromyalgic syndrome have specific abnormalities of skeletal homeostasis. Radioisotopic evaluation of skeletal remodeling showed higher Fogelman index and increased 24-hour pyrophosphate retention in the group of fibromyalgics (n=28) when compared to the control group (n=16). Bone density (lumbar vertebrae and femoral neck) was not significantly different from control subjects. These data might suggest an accelerated bone metabolism in these patients.     

大豆异黄酮对大鼠骨密度及骨代谢生化指标的影响

目的 研究植物雌激素-大豆异黄酮对大鼠骨密度及骨代谢生化指标的影响。方法 将断乳Wister大鼠按体重随机分为4组，分别给予基础饲料和不同剂量的大豆异黄酮。每周称体重，调整给食量。12周后处死大鼠，取脏器称重，计算脏体比值；剥离股骨，测骨矿物质含量(BMC)、骨密度(BMD)和骨钙、骨磷的含量；对血清中骨形成生化指标碱性磷酸酶、骨钙素和骨吸收生化指标抗酒石酸酸性磷酸酶进行检测，同时测定雌激素-雌二醇(E2)的含量。结果 具有弱雌激素样作用的大豆异黄酮对实验大鼠的子宫、卵巢无刺激作用。与对照组相比，给予大豆异黄酮能提高BMC、BMD及骨钙含量，并随剂量的增加而增大。大豆异黄酮可影响骨代谢，高剂量的大豆异黄酮(41．6mg／kg)同时抑制骨形成和骨吸收，使骨转化率降低，但对骨吸收的作用大于骨形成。给予大豆异黄酮组血清雌激素水平大于对照组。结论 大豆异黄酮通过调整骨代谢生化指标的活性，提高大鼠的骨钙含量和骨密度，可预防骨质疏松的发生。     

Osteoprotegerin: a valid new marker of bone turnover in post-menopausal osteoporosis?

Abstract An increase of setum osteoprotegerin has been found in post-menopausal women, that is positively correlated with age and bone markers, negatively with bone mass. In 25 post-menopausal women (mean age, 63±8 years) we measured serum levels of osteoprotegerin, total and bone alkaline phosphatase, osteocalcin, urinary deoxypyridinoline and bone mineral density of the lumbar spine and femur.Osteoprotegerin and bone markers did not differ from range of normal values. Bone mineral density appeared markedly reduced both at the spine and the femur.A significant correlation between osteoprotegerin and age, duration of menopause, osteocalcin and bone alkaline phosphatase was found. No correlation was found between osteoprotegerin and bone mineral density in all measured skeletal sites. In conclusion, osteoprotegerin does not appear to be an interesting parameter for the evaluation of bone turnover in post-menopausal osteoporosis.     

The relation between lifestyle factors and biochemical markers of bone turnover among early postmenopausal women

We examined the associations of two biochemical markers of bone turnover with lifestyle factors in 340 postmenopausal women in Hawaii, ages 45–59 years, from the Early Postmenopausal Intervention Cohort. Physical activity, calcium supplement use, smoking and alcohol use in the prior 2 weeks were measured and examined as independent variables in multiple regression analyses with bone turnover markers as dependent variables, adjusted for weight, height, whole body bone mass, serum estradiol, years since menopause, and ethnicity. Calcium supplement and alcohol use were significantly associated with reduced levels of urinary type I collagen cross-linked N-telopeptides (NTX). The mean NTX level was 12% lower among women using ≥250 mg of calcium supplements per day as compared with other women, and 20% lower among alcohol users compared with nonusers. Both calcium supplement use and alcohol intake were associated with lower mean serum osteocalcin (a marker of bone formation) and NTX z-scores. By contrast, smoking was associated with lower osteocalcin levels, without any effect on NTX. The osteocalcin level was 12% lower among smokers compared with nonsmokers. In addition, the z-score difference between NTX and osteocalcin was significantly associated with smoking, with a shift towards more NTX than osteocalcin. Physical activity was not significantly associated with either of the markers. These findings suggest that biochemical markers may help to identify lifestyle factors that affect bone, and provide estimates of the relative magnitude of these effects on bone formation and resorption, independent of each other.     

The duration of exercise as a regulator of bone mass

Exercise is associated with increased peak bone mineral density (BMD). To determine the relationship between the duration of exercise and BMD, we measured BMD of the axial and appendicular skeleton by dual-energy X-ray absorptiometry (DXA), and speed of sound (SOS), broadband attenuation (BUA), and stiffness index by quantitative ultrasound (QUS) of the calcaneus, in 67 active male national soccer players (mean age 23 years, range 17-35), which included 23 premier-league players exercising 12 h/week (range 8-18), 23 third-league players exercising 8 h/week (range 3-18), and 21 sixth-league players exercising 6 h/week (range 2-10). Results were compared with 24 sedentary age- and gender-matched controls and presented as mean +/- SEM. BMD was higher in all weight-bearing regions for the whole group relative to controls (BMD: total body 6.8 +/- 0.7%, leg 9.6 +/- 0.8%, lumbar spine 13.2 +/- 1.2%, femoral neck 12.7 +/- 1.2% [all p < 0.001]; calcaneus SOS 4.2 +/- 0.3%, BUA 8.7 +/- 1.5%, and stiffness index 24.2 +/- 2.0% [all p < 0.01]). No differences were found in head or arm BMD. There were no differences in BMD or QUS measurements when comparing soccer players exercising for different activity durations. Duration of activity correlated with BMD weight-loaded regions and with QUS, provided it was less <6 h/week (p < 0.01 respectively), but not when exercising more frequently. Femoral neck BMD increased by 3.3% across every hour increase in activity in those with 0-6 h of exercise/week and by 0.7% in those exercising more than this (p < 0.01). We conclude that, in national-league soccer, the BMD needed to attain a bone strength commensurate with that of duration of activity is achieved by 6 h of exercise per week. Beyond this, additional exercise confers no higher BMD. The skeleton adapts to the prevalent level of exercise intensity required and no further.     

广场舞对绝经期后骨质疏松患者的骨密度和骨转换指标影响的研究

目的观察广场舞对绝经后骨质疏松患者的骨密度、骨转换指标的影响。方法研究组:口服钙尔奇D600 mg每日1次的同时,联合广场舞运动方法干预,每周5次,每次平均0.5~1.0小时;对照组:单纯采用口服钙尔奇D600 mg每日1次,观察两组实验前及实验干预6个月后受试者骨密度、骨转换指标变化、骨痛。结果 (1)骨密度变化:研究组治疗6个月后,腰椎L2-4、股骨颈部的骨密度较治疗前明显升高(P0.05),Ward’s区骨密度无显著性改变。而对照组各部位骨密度较前无明显改变(P0.05)。(2)血生化中血钙、血磷及碱性磷酸酶指标值:两组生化指标在治疗前后无统计学差异(P0.05);治疗6个月后P1NP的水平明显升高(P0.05),β-CTX水平未有明显改变(P0.05)。(3)疼痛程度改善情况:两组治疗前后疼痛分级比较,研究组疼痛明显改善。结论广场舞运动能部分改善绝经后妇女骨密度,并且可以缓解骨质疏松引起的疼痛,是一种切实可行的预防和治疗骨质疏松症的临床方案。     

运动训练与骨生长代谢的研究进展

采用文献研究法从运动训练对运动员(包括力量性、耐力性、速度性、柔韧性运动项目)骨形态结构、骨量、骨密度的影响及其相互间的差异等方面进行综述.提出目前不同运动项目对运动员骨代谢影响的研究不够全面,大多只集中于骨形态结构、骨量和骨密度阶段,没有深入探讨其机制,涉及到干细胞层面的研究尚未全面展开.     

Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover

Introduction: The purpose of this study was to compare age-related differences in osteoprotegerin (OPG) in relationship with BMD and the serum bone markers osteocalcin (OC), collagen crosslinks (CTX), and tartrate-resistant acid phosphatase 5b (TRACP-5b). Methods: Data were derived from a cross-sectional study on bone health in a random sample of community-dwelling adults aged 30 to 85 years in the Reykjavik area in Iceland. All subjects had whole body, hip, and lumbar spine BMD measured (by DXA), gave blood samples, and answered a thorough questionnaire on medications and medical history. We assessed relationships using the Spearman correlation coefficient, partial correlation, and multivariable linear regression. Men and women were analyzed separately. Results: Of 2,310 subjects invited over 2 years, 1,630 participated. After excluding individuals with diseases and medications affecting bone metabolism, 517 women (age 56.1 ± 16.9 years) and 491 men (age 58.7 ± 14.9 years) remained for analysis. OPG increased steadily with age in both genders without a gender difference. In women, BMD at all sites declined steadily after age 50. In men, BMD remained relatively stable until age 70, after which it declined significantly. After controlling for age, BMI, and other confounding variables, OPG showed only a borderline positive relationship with whole body BMD in men (P=0.10), but the relationship was nonsignificant in women. In multivariable models, OPG was inversely related to TRACP-5b (P=0.002) and positively with OC (P=0.007), the OC/TRACP-5b (P=0.001) and OC/CTX (P=0.02) ratios in women. Among men, multivariable models showed a positive association between OPG and OC (P=0.05) and OC/TRACP-5b (P<0.009). Conclusions: We conclude that serum OPG levels are associated with a profile of bone turnover markers favoring bone formation, suggesting that OPG may be protective against age-related bone loss. Longitudinal studies are needed to address that issue.     

Hormonal profiles and biochemical indices of bone turnover in Indian women

Summary The study establishes Indian referent database for bone turnover markers. The levels of markers decreased across the four quartiles of BMD showing a negative correlation with BMD. The study depicts that levels of hormones and bone turnover makers can aid in identifying women at risk for osteoporosis. Introduction Biochemical markers of bone turnover reflect changes in bone metabolism earlier and aid in the management of osteoporosis. Since a referent database for Indian women is lacking, the study was initiated to establish the same and suggest that hormonal profiles and markers of bone turnover can aid in identifying women at risk for osteoporosis. Methods Osteocalcin (OC), bone specific alkaline phosphatase ((BSAP), C-terminal crosslinking telopeptide of type-I collagen (CTX-I), deoxypyridinoline (DPD), follicle-stimulating hormone (FSH) and estrone glucuronide (E₁G) were measured in 365 Indian women (20–70 years) and correlated with BMD measurements by dual energy absorptiometry (DXA) using one way analysis of variance (ANOVA). Results The mean levels of bone resorption markers; CTX-I and DPD increased significantly across the age showing a negative correlation with BMD. The increase in levels of CTX-I and DPD was significantly higher (p < 0.0001) as compared to the femoral and spinal BMD, which dropped only 30–36%. The levels of bone turnover markers and FSH decreased across the four quartiles of spinal and femoral BMD showing a negative correlation whereas E₁G levels increased across the four quartiles. Conclusion The bone turnover markers were comparatively low in cohort of Indian women studied.     

Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study

The effect of vitamin K₂ (menatetrenone) on bone turnover was investigated in postmenopausal patients with osteoporosis. A 6-month open-label, randomized prospective study was conducted in 109 patients. The control group (n = 53) received calcium aspartate (133.8 mg of elemental calcium daily), while the menatetrenone group (n = 56) received 45 mg of menatetrenone daily for 6 months. Serum and urinary levels of bone turnover markers were monitored. The serum level of undercarboxylated osteocalcin (uc-OC) was significantly lower (P < 0.001) in the menatetrenone group than in the control group (at 1 month), while there was a higher level of osteocalcin containing gamma-carboxylated glutamic acid (Gla-OC) in the menatetrenone group than the control group (P = 0.018). Significant differences of uc-OC and Gla-OC between the two groups were observed from 1 month onward. In addition, a higher level of intact osteocalcin was found in the menatetrenone group compared with the control group after 6 months (P = 0.006). Assessment of bone resorption markers showed that menatetrenone therapy was associated with significantly higher urinary N-telopeptide of type I collagen (NTX) excretion compared with the control group after 6 months, while there was no significant difference of urinary deoxypyridinoline excretion between the two groups. In conclusion, one month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin, while urinary NTX excretion was increased after 6 months of treatment. Further investigations are required to determine whether the effects of menatetrenone on bone turnover are associated with fracture prevention.     

Bone mineral density and bone turnover markers in children with chronic renal failure

Bone mineral density (BMD) at lumbar spine (L₂-L₄) was measured by dual-energy X-ray absorptiometry (DEXA) in 21 children with predialysis chronic renal failure (CRF) and 44 children with end-stage renal failure (ESRF) on regular hemodialysis. BMD results were expressed as Z-scores. Osteopenia was documented in 13 predialysis patients (61.9%) and 26 patients (59.1%) with ESRF. No significant correlation was observed between Z-scores and the duration of CRF or estimated creatinine clearance. In osteopenic children there was a negative correlation between Z-scores and serum phosphorus (r=–0.61, P=0.004), intact parathyroid hormone (iPTH) (r=–0.47, P=0.03), and bone-specific alkaline phosphatase (r=–0.52, P=0.02) and a positive correlation with total calcium (r=0.41, P=0.07) and 25-hydroxycholecalciferol (r=0.53, P=0.02). Osteopenic children who had iPTH values 200 pg/ml were more osteopenic than those who had lower iPTH levels (P=0.006). In conclusion, osteopenia, assessed by DEXA, is frequent in children with CRF. It occurs early irrespective of the duration or the severity of CRF. In children with ESRF the degree of osteopenia is correlated with laboratory markers of renal osteodystrophy and patients with biochemical findings of secondary hyperparathyroidism are more osteopenic than the others.     

Serum bone Gla protein as a marker of bone turnover in acromegaly

Summary Serum bone Gla protein, a sensitive and specific marker of bone turnover, was measured in 35 acromegalic patients (14 untreated, 8 clinically active, and 13 cured) and 21 controls. We also examined 10 acromegalic patients before and after transsphenoidal surgery. Untreated and clinically active acromegalic patients had significantly higher serum bone Gla protein concentrations than the control subjects. Other nonspecific biochemical markers of bone metabolism, such as urinary hydroxyproline and urinary calcium, were also present in significantly greater amounts in active acromegalic patients. After treatment, a significant decrease in levels was observed, with return to control levels. In acromegalic patients, positive correlations were found among serum bone Gla protein and serum growth hormone and serum insulin-like growth factor I levels, as well as among levels of insulin-like growth factor I and serum phosphorus, serum alkaline phosphatase, and urinary hydroxyproline. These results suggest that serum bone Gla protein is a sensitive marker of the action of growth hormone in bone metabolism in acromegaly, a role that is probably mediated by insulin-like growth factor I.     

重度围绝经期牙周病妇女骨密度及骨转换指标表达分析

目的分析重度围绝经期牙周病（牙周病指数6～7）妇女骨密度及骨转换指标。方法连续选择28例重度围绝经期牙周病妇女,入选对象均接受腰椎密度、双侧股骨上端BMD、骨钙素和碱性磷酸酶等指标测定,并与31例同期就诊围绝经期牙周病妇女（牙周病指数4～5）和27例同期在笔者所在医院进行体检结论健康同龄女性（对照组）比较。结果重度牙周病组的腰椎L1～4和左、右股骨Neck的BMD测定值均明显低于牙周病组和对照组,而血清BGP和AKP测定值均明显高于后两组（P均〈0.05）。结论重度围绝经期牙周病妇女存在着明确的身体各部位BMD测定值下降,同时各项骨转换指标明确增加。     

绝经后妇女血清OPN水平与骨密度及骨转换水平的相关性研究

目的：研究绝经后女性血清骨桥蛋白（OPN）水平与骨密度（BMD）、骨标志物的关系,探索OPN在绝经后骨质疏松症（ PMOP）中的临床应用价值。方法对125名绝经后女性进行研究,双能X线骨密度仪测量腰1－4及左股骨颈BMD,测定血中I型原胶原N－端前肽（PINP）、β－胶原降解产物（β－CTX）、25羟维生素D、甲状旁腺素、OPN、骨钙素（OC）、钙（Ca）和磷（P）。结果①骨质疏松组血清OPN水平明显高于骨量减少和正常组（ F＝0．118,P＝0．000）;②血清OPN水平与BMD（腰1－4,左股骨颈）、血Ca显著负相关,与年龄、β－CTX、OC显著正相关（ P均＜0．05）;③多元线性回归分析结果表明,左股骨颈骨密度（B,－11．971;SE,2．383;标准系数,－0．402;P＝0．000）、血钙（B,－6．696;SE,2．383;标准系数,－0．225;P＝0．006）是OPN水平独立预测因子。结论高血清OPN水平与低BMD、高β－CTX水平及钙缺乏相关,该结果丰富了现有的临床证据,为防治PMOP提供了新的思路。     

骨代谢生化指标随年龄的变化及其临床意义

本文收集了北京地区１９２８名不同年龄（０～８７岁）健康人及５３４５例２０余种疾病患者空腹尿及血，并对其骨代谢生化指标进行测定。结果表明：血清２５羟基维生素Ｄ（２５ＯＨＤ），碱性磷酸酶（ＡＬＰ），骨钙素（ＢＧＰ），甲状旁腺激素（ＰＴＨ），尿Ⅰ型胶原交联Ｎ末端肽与肌酐比值（ＮＴＸ／Ｃｒ）及羟脯氨酸与肌酐比值（ＨＯＰ／Ｃｒ）与年龄显著相关。血清２５ＯＨＤ，ＢＧＰ，尿ＮＴＸ／Ｃｒ及ＨＯＰ／Ｃｒ可用于预测骨量。１，２５（ＯＮ）２Ｄ３，２５ＯＨＤ，ＮＴＸ／Ｃｒ和ＮＯＰ／Ｃｒ可用于区分绝经前与绝经后骨质疏松妇女。与年龄有关的骨丢失可能与１，２５（ＯＨ）２Ｄ３的降低、ＰＴＨ的升高及肾功能减退有关；绝经后骨丢失与雌激素缺乏有关。     

骨转换生化标志物的研究新进展

骨转换生化标志物是在骨骼重建过程中释放于血液、尿液中的或其他分泌物,是能够被检测出来的一些活性物质,其具有稳定性好,特异性强,敏感性高等优点。虽然骨转换生化标志物不能作为诊断骨质疏松症的金标准,但是联合骨密度,我们可以更早地了解骨转换的动态,在骨转换平衡状态的评估、骨代谢疾病的鉴别诊断、抗骨质疏松治疗疗效监测等方面有重要作用。目前,一些传统的骨转换生化标志物(BALP、OC、PⅠNP、TRACP、DPD、CTX)已经成熟运用于临床和科研中,新发现的骨转换生化标志物(BSP、POSTN、SO、Cat K、OCIL等)在骨质疏松症和骨代谢疾病诊疗方面也有一定的应用,其灵敏性、特异性、稳定性仍需要进一步研究确认。本文从传统的骨转换生化标志物和新发现的骨转换生化标志物的研究进展及其在临床上的应用进行了简单的综述。     

两种糖皮质激素导致骨质疏松过程中骨量、骨转换标志物及雌激素水平的差异

目的 对比泼尼松龙（PRE）和地塞米松（DXM）致骨质疏松过程中对大鼠骨量和骨转换标志物、雌激素水平的差异。方法 选取3月龄SPF级雌性大鼠46只,随机分成4组：基线组（BL组）6只、年龄对照组（AM组）12只、泼尼松龙组（PRE组）14只、地塞米松组（DXM组）14只。BL组于实验开始时麻醉处死,其余各组分别予常规饲养,PRE组以5mg/kg PRE每天一次皮下注射,DXM组以1mg/kg DXM每周两次皮下注射,于干预后1、2、3个月（M1、M2、M3）分3批麻醉处死取材。每次取材时立即取子宫、肾上腺称重,并收集血清以检测血清内雌激素、PINP及β-CTX水平、收集腰1-3椎体以检测腰椎骨密度（BMD）。结果 PRE组各时间点BMD值[（0.183±0.027、0.230±0.005、0.259±0.014）g/cm2]及DXM组各时间点BMD值[（0.191±0.010、0.208±0.012、0.200±0.004）g/cm2]均较AM组[（0.251±0.014、0.275±0.009、0.281±0.008）g/cm2]明显下降（P＜0.05）,其中DXM组下降更为显著（P＜0.01）,且在M2及M3,DXM组BMD值明显低于PRE组（M2：P＜0.05;M3：P＜0.01）。PRE组干预初期,其血清雌激素水平（36.54±20.40μg/L）较AM组（148.74±40.33 μg/L）明显降低（P＜0.01）,但随着干预时间延长, M3时（130.85±18.95 μg/L）增长至与AM组（126.64±69.12 μg/L）相接近水平（P＞0.05）,但在DXM干预下,雌激素水平在各时间点[（93.13±31.27、91.77±33.14、98.83±10.58）μg/L]均低于AM组[（148.74±40.33、140.01±28.46、126.64±69.12）μg/L]（P＜0.05）。两种GC干预下,PINP及β-CTX均显著高于AM组（P＜0.01）,且PRE干预后各时间点PINP水平[（1410.33±882.40、2089.23±1623.61、1546.88±644.68）μg/L]显著高于DEX组[（258.70±139.42、220.89±92.82、483.36±225.82）μg/L]（P＜0.05）。结论 地塞米松诱导骨量减少的能力明显强于泼尼松龙,这可能与其更大程度地降低血清雌激素水平以及更有效地限制成骨有关。     

复方贞术调脂胶囊对糖皮质激素诱导骨质疏松大鼠血脂和骨转换指标的研究

目的观察复方贞术调脂胶囊(FTZ)对糖皮质激素诱导骨质疏松大鼠血脂水平和血清骨转换指标的影响。方法 3月龄SPF级雄性SD大鼠32只,随机等分为4组:Nrm组为正常对照组,Met组为皮下注射甲强龙(Met)5 mg/(kg·d),每周5次,FTZL组和FTZH组在Met组基础上每日分别给予低剂量FTZ(1.5g/kg)和高剂量FTZ(6g/kg)灌胃,实验期为12w。ELISA法测量血脂四项(TC、TG、HDL-C、LDL-C),血清中Ⅰ型前胶原氨基末端前肽(N-terminal propeptide of type I procollagen,PINP)、Ⅰ型胶原羧基端肽(C-terminal cross-linking telopeptide of type I collagen,β-CTX)和OC(osteocalcin)含量。结果 Met组大鼠体质量、血清HDL和OC、P1NP均显著低于Nrm组相应指标(Ρ0.05,Ρ0.01,Ρ0.001),血清TC、TG、LDL和β-CTX显著高于Nrm组(Ρ0.01);FTZL组大鼠的体质量和P1NP较Met组有升高趋势,β-CTX有降低趋势,但两组间各指标均无显著性差异(Ρ0.05);FTZL组大鼠血清HDL和OC显著高于Met组(Ρ0.05),血清TC、TG和LDL显著低于Met组(Ρ0.05);FTZH组大鼠体质量、血清HDL、OC和P1NP显著高于Met组相应指标(Ρ0.001,Ρ0.01,Ρ0.05),血清TC、TG、LDL和β-CTX显著低于Met组(Ρ0.05);FTZH组大鼠血清TC、HDL、LDL和OC显著高于FTZL组(Ρ0.05,Ρ0.01)。结论 FTZ对糖皮质激素诱导骨质疏松大鼠的血脂和骨转换有一定的改善作用。